LAS VEGAS, Nov. 2 /PRNewswire-FirstCall/ -- VMT Scientific Inc. (OTC: VMTF) announces its globally patented breakthrough technology that may make the need for Peripheral Vascular Disease (PVD) and Diabetic associated amputations obsolete. Its technology, the VasCir(TM) system is designed to re-establish microvascularization and Tissue Histogenesis. Engineering and the Science: VMT Scientific Inc. has patented a unique design of sophisticated negative pressure technology that leads to the first controlled and repeatable method of soft tissue histogenesis. The technology also has identified several additional unique medical applications and is protected both domestically and internationally by patents. The patented methodology and technology is focused on the values perceived in the areas of neurology, vascular disease, pediatric medicine and reconstructive/aesthetic medicine. VMT Scientific Inc. is focused to mature this technology through additional objective evidence with clinical trials. The clinical data will be used to file for clearance with the FDA for the therapeutical treatment of "Diabetic Neuropathy and PVD." Upon clearance, VMT Scientific Inc. will make available license rights of the VasCir(TM) to manufacturers and distribution organizations worldwide. The Technological FACTS are: * Tissue histogenesis is well known and documented. * The independent production of new tissue is produced through proper stimulation and the benefits have been shown to last for years. * Damaged tissues respond with accentuated healing capabilities. * The VasCir(TM) system has demonstrated its ability to "non-invasively" control blood flow with increases up to 300%. * DYNAMICALY controlled increases in blood flow have a dramatic immune system response. * DYNAMICALY controlled increases in blood flow to areas previously ischemic facilitates the regeneration of neurological tissues. Please visit VMT Scientific, Inc.'s Web site for more information: www.vmtf.com This Press Release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should not place undue reliance on these forward-looking statements. These statements involve risks and uncertainties that could cause actual results to differ materially from those suggested in the forward- looking statements, particularly those risks and uncertainties inherent in the process of developing, manufacturing and distributing medical products and Clinical trials. Factors that may cause such a difference include risks related to VMT Scientific Inc.'s limited operating history, risks associated with completing development and obtaining FDA medical approvals, successful patent protection and prosecution, successful sale of licensed technology nationally or internationally. VMT Scientific technology will not meet with market acceptance, the risk of future warranty and product liability claims, the uncertainty of VMT Scientific Inc.'s future access to capital to sustain operations, achieve profitability or continue as a going concern, the failure by VMT Scientific Inc.'s to secure and maintain relationships with suppliers, manufacturers and other third parties, reliance on key employees, and dependence on intellectual property. World events, national economy and/or other conditions and circumstances beyond our control. Further information on the factors and risks that could affect VMT Scientific Inc.'s business, financial condition and results of operations. These forward-looking statements are based on information and management's expectations as of the date hereof. Future results may differ materially from our current expectations. VMT Scientific Inc.'s disclaims any intent or obligation to update whose forward-looking statements. "Saving feet and limbs is what it's all about" Says VMT Scientific Inc.
SOURCE VMT Scientific, Inc.